HeartSciences shares rise 10.26% intraday as Ascendiant Capital raises price target to $9.20 on Buy rating.

HeartSciences surged 10.26% intraday after Ascendiant Capital analyst Lucas Ward maintained a Buy rating on the stock and raised the price target from $9 to $9.2. The upgraded price target signaled increased confidence in the company’s prospects, likely encouraging investor buying activity during regular trading hours. The move aligns with the analyst’s positive outlook, which may have reinforced short-term momentum for the stock.